CrowdStrike Slips Despite VAST Data AI Security Partnership

BenzingaBenzinga
|||1 min read
Key Takeaway

CrowdStrike shares fell 0.79% despite announcing an AI security partnership with VAST Data. Stock remains significantly below recent averages amid broader technical weakness.

CrowdStrike Slips Despite VAST Data AI Security Partnership

CrowdStrike Holdings Inc. shares declined 0.79% during premarket trading Thursday, continuing a recent pullback despite announcing a strategic partnership with VAST Data to strengthen artificial intelligence-powered security capabilities. The collaboration aims to integrate advanced AI security features, though investor appetite appeared muted in early trading activity.

The stock's performance reflects broader technical weakness, with shares trading 12.5% below their 20-day moving average and 20.3% below their 100-day moving average, signaling a sustained downward trend despite positive corporate developments. The extended pullback has created a significant gap between current price levels and recent highs, suggesting investor caution may be overriding partnership optimism.

Wall Street's analyst community has maintained confidence in the cybersecurity company's long-term prospects, with consensus ratings remaining at Buy and a median price target of $549 per share. This disconnect between bullish analyst outlooks and current market valuation suggests investors may be factoring in near-term headwinds or awaiting additional catalysts before reassessing positions.

Source: Benzinga

Back to newsPublished Feb 26

Related Coverage

GlobeNewswire Inc.

Corcept Therapeutics Faces Class Action Over FDA Rejection; Stock Crashed 50%

Corcept Therapeutics faces securities fraud lawsuit after FDA rejected relacorilant application. Stock plummeted 50.4% following December rejection. Investor deadline April 21, 2026.

CORT
Investing.com

D-Wave's 44% Plunge Masks Quantum Leap: Growth Story vs. Valuation Reality

D-Wave ($QBTS) fell 44% in 2026 despite strong bookings exceeding 2025 totals and $30M in major deals. Analysts see 132% upside, but 237x sales valuation remains extreme.

QBTS
GlobeNewswire Inc.

OneMain Holdings Faces Multi-State Securities Probe Over Alleged Lending Fraud

Pomerantz Law Firm investigates $OMF following multi-state lawsuit alleging deceptive lending practices. Stock tumbles 5.38% on fraud allegations.

OMF
Investing.com

Refiner Rally on Borrowed Time: Why Small-Cap Oil Stocks Face Sharp Reversal

Small-cap refiners $CVR and $PBF surged on widening crack spreads from Iran tensions, but face margin compression risks as spreads normalize, with overbought technicals signaling profit-taking opportunity.

PBFCVI
GlobeNewswire Inc.

Boston Scientific Faces Securities Fraud Lawsuit Over Overstated EP Growth Claims

Boston Scientific faces class action lawsuit alleging material misstatements about electrophysiology growth. Stock fell 17.6% after disclosing slower market growth and competitive pressures.

BSX
GlobeNewswire Inc.

Nektar Therapeutics Faces Class Action Over Failed Trial Data Disclosure

Pomerantz LLP filed securities fraud class action against Nektar Therapeutics, alleging false statements about clinical trial enrollment procedures led to trial failure and stock decline.

NKTR